Maria A Parker1, Stacey C Sigmon2, Andrea C Villanti2. 1. Department of Psychiatry, Vermont Center on Behavior & Health, University of Vermont, 1 South Prospect Street, SATC-UHC, Burlington, VT 05401, United States. Electronic address: maria.parker@uvm.edu. 2. Department of Psychiatry, Vermont Center on Behavior & Health, University of Vermont, 1 South Prospect Street, SATC-UHC, Burlington, VT 05401, United States; Department of Psychological Science, Vermont Center on Behavior & Health, University of Vermont, 1 South Prospect Street, SATC-UHC, Burlington, VT 05401, United States.
Abstract
INTRODUCTION: Individuals with drug use disorders or affective disorders have higher cigarette smoking prevalence and smoking intensity and are less likely to quit than the general population. We sought to estimate the prevalence of cigarette smoking by drug use and psychiatric diagnoses and to explore to what extent a co-occurring diagnosis was associated with current smoking. METHODS: Data were derived from the most recent National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III, 2012-2013; n = 36,309). Cigarette smoking status was examined among those with any past-year or lifetime drug use disorders (i.e., alcohol, cannabis, opioid, cocaine) or affective disorders (i.e., mood, anxiety). Diagnoses were assessed using the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-5). RESULTS: Adjusting for sociodemographic characteristics, those with drug use disorders (past-year AOR = 3.3, 95% CI: 3.0, 3.6; lifetime AOR = 3.2, 95% CI: 3.0, 3.5) and those with affective disorders (past-year AOR = 1.7; 95%CI: 1.5, 1.8, lifetime AOR = 1.3, 95% CI: 1.2; 1.4), had higher odds of current cigarette smoking compared to individuals with no diagnosis. The odds of current cigarette smoking was significantly higher in individuals with both drug use disorders and affective disorders compared to those with either a drug use or affective disorder or no disorder (past-year AOR = 5.1; 95% CI: 4.3, 5.9, lifetime AOR = 4.3; 95% CI: 3.8, 4.7). CONCLUSIONS: Approximately 30% of the population had a past-year drug use or affective disorder, 17% of whom report both. The combination of both diagnoses produced a 1.5 to 3-fold higher correlation with smoking than either alone.
INTRODUCTION: Individuals with drug use disorders or affective disorders have higher cigarette smoking prevalence and smoking intensity and are less likely to quit than the general population. We sought to estimate the prevalence of cigarette smoking by drug use and psychiatric diagnoses and to explore to what extent a co-occurring diagnosis was associated with current smoking. METHODS: Data were derived from the most recent National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III, 2012-2013; n = 36,309). Cigarette smoking status was examined among those with any past-year or lifetime drug use disorders (i.e., alcohol, cannabis, opioid, cocaine) or affective disorders (i.e., mood, anxiety). Diagnoses were assessed using the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-5). RESULTS: Adjusting for sociodemographic characteristics, those with drug use disorders (past-year AOR = 3.3, 95% CI: 3.0, 3.6; lifetime AOR = 3.2, 95% CI: 3.0, 3.5) and those with affective disorders (past-year AOR = 1.7; 95%CI: 1.5, 1.8, lifetime AOR = 1.3, 95% CI: 1.2; 1.4), had higher odds of current cigarette smoking compared to individuals with no diagnosis. The odds of current cigarette smoking was significantly higher in individuals with both drug use disorders and affective disorders compared to those with either a drug use or affective disorder or no disorder (past-year AOR = 5.1; 95% CI: 4.3, 5.9, lifetime AOR = 4.3; 95% CI: 3.8, 4.7). CONCLUSIONS: Approximately 30% of the population had a past-year drug use or affective disorder, 17% of whom report both. The combination of both diagnoses produced a 1.5 to 3-fold higher correlation with smoking than either alone.
Authors: Stephen T Higgins; Allison N Kurti; Ryan Redner; Thomas J White; Diana R Keith; Diann E Gaalema; Brian L Sprague; Cassandra A Stanton; Megan E Roberts; Nathan J Doogan; Jeff S Priest Journal: Prev Med Date: 2016-02-21 Impact factor: 4.018
Authors: Bridget F Grant; Rise B Goldstein; Sharon M Smith; Jeesun Jung; Haitao Zhang; Sanchen P Chou; Roger P Pickering; Wenjun J Ruan; Boji Huang; Tulshi D Saha; Christina Aivadyan; Eliana Greenstein; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2014-12-08 Impact factor: 4.492
Authors: S Patricia Chou; Risë B Goldstein; Sharon M Smith; Boji Huang; W June Ruan; Haitao Zhang; Jeesun Jung; Tulshi D Saha; Roger P Pickering; Bridget F Grant Journal: J Clin Psychiatry Date: 2016-10 Impact factor: 4.384
Authors: Jason D Robinson; Yong Cui; Maher Karam-Hage; George Kypriotakis; Francesco Versace; Nassima Ait-Daoud Tiouririne; Robert M Anthenelli; Paul M Cinciripini Journal: Alcohol Clin Exp Res Date: 2022-01-31 Impact factor: 3.455
Authors: Kelly Williams; Amanda A Maise; Jaspreet S Brar; Adelina Malito; Leslie Washington; David Loveland; Tracy Carney; Duncan Bruce; Patricia Schake; James Schuster Journal: Community Ment Health J Date: 2022-10-22
Authors: Felicia N Williams; Lori Chrisco; Paula D Strassle; Sarah L Laughon; Sanja Sljivic; Kamil Nurczyk; Rabia Nizamani; Booker T King; Anthony Charles Journal: Int J Burns Trauma Date: 2020-08-15
Authors: Jacqueline M Vink; Jorien L Treur; Joëlle A Pasman; Arnt Schellekens Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-09-10 Impact factor: 3.358
Authors: Andrea C Villanti; S Elisha LePine; Catherine Peasley-Miklus; Julia C West; Maria Roemhildt; Rhonda Williams; William E Copeland Journal: Child Adolesc Ment Health Date: 2022-03-06 Impact factor: 4.111